Compositions and methods for the treatment of cancer
AssigneeVedanta Biosciences, Inc.
InventorBernat Olle
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, methods, and kits for the treatment of cancer. The disclosure also provides compositions, methods, and kits that suppress adverse events caused by anticancer therapy.
Claims75
A method of treatment comprising administering to a subject undergoing anticancer therapy a suppressing agent that suppresses an adverse event caused by the anticancer therapy.
A method of treatment comprising administering a pharmaceutically effective amount of anticancer therapy to a subject in need thereof and administering to the subject a suppressing agent that suppresses an adverse event caused by the anticancer therapy.
A method of treatment comprising administering to a subject in need thereof a suppressing agent followed by a pharmaceutically effective amount of anticancer therapy.
A method of treatment comprising administering to a subject in need thereof a combination of a suppressing agent and a pharmaceutically effective amount of anticancer therapy.
A method of treatment comprising administering a pharmaceutically effective amount of anticancer therapy to a subject in need thereof, determining if an adverse event occurs in the subject, and administering to the subject a suppressing agent that suppresses the adverse event.
A method of treatment comprising administering a pharmaceutically effective amount of anticancer therapy to a subject in need thereof, determining if an adverse event occurs in the subject, wherein if an adverse event occurs, administering to the subject a suppressing agent that suppresses the adverse event.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of one or more anticancer agents.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of one or more cytokines.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of one or more costimulatory agents.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of an anticancer live bacterial product.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of an immune checkpoint inhibitor and an anticancer live bacterial product.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-1 inhibitor and an anticancer live bacterial product that induces CD8+ T-cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-1 inhibitor and an anticancer live bacterial product that induces Th17 cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-1 inhibitor and an anticancer live bacterial product that induces Th1 cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-1 inhibitor and an anticancer live bacterial product that comprises bacterial strains of species associated with increased efficacy in anticancer treatment with a PD-1 inhibitor.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-L1 inhibitor and an anticancer live bacterial product that induces CD8+ T-cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-L1 inhibitor and an anticancer live bacterial product that induces Th17 cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-L1 inhibitor and an anticancer live bacterial product that induces Th1 cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a PD-L1 inhibitor and an anticancer live bacterial product that comprises bacterial strains of species associated with increased efficacy in anticancer treatment with a PD-L1 inhibitor.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a CTLA-4 inhibitor and an anticancer live bacterial product that induces CD8+ T-cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a CTLA-4 inhibitor and an anticancer live bacterial product that induces Th17 cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a CTLA-4 inhibitor and an anticancer live bacterial product that induces Th1 cells.
The method of any one of the preceding claims, wherein the anticancer therapy comprises the administration of a CTLA-4 inhibitor and an anticancer live bacterial product that comprises bacterial strains of species associated with increased efficacy in anticancer treatment with a CTLA-4 inhibitor.
The method of any one of the preceding claims, wherein the suppressing agent is an agent that suppresses the immune response.
The method of any one of the preceding claims, wherein the suppressing agent is a suppressing live bacterial product.
The method of any one of the preceding claims, wherein the adverse event is an undesired immune response.
The method of any one of the preceding claims, wherein the adverse event is colitis.
The method of any one of the preceding claims, wherein the adverse event is dermatological toxicity.
The method of any one of the preceding claims, wherein the adverse event is diarrhea.
The method of any one of the preceding claims, wherein the adverse event is hepatotoxicity.
The method of any one of the preceding claims, wherein the adverse event is hypophysitis.
The method of any one of the preceding claims, wherein the adverse event is autoimmune thyroid disease.
The method of any one of the preceding claims, wherein the suppressing agent is administered after the occurrence of the adverse event.
The method of any one of the preceding claims, wherein the suppressing agent is administered prior to the occurrence of the adverse event.
The method of any one of the preceding claims, wherein the method further comprises repeating the anticancer therapy.
The method of any one of the preceding claims, wherein the method further comprises repeating the administration of the suppressing agent.
The method of any one of the preceding claims, wherein the method further comprises repeating the anticancer therapy and repeating the administration of the suppressing agent.
The method of any one of the preceding claims, wherein the method further comprises determining if an adverse event occurs.
The method of any one of the preceding claims, wherein the subject is treated with antibiotics prior to administration of the suppressing agent.
The method of any one of the preceding claims, wherein multiple doses of the suppressing agent are administered.
The method of any one of the preceding claims, wherein the suppressing agent is administered after the completion of one round of the anticancer therapy.
The method of any one of the preceding claims, wherein the suppressing agent is administered at least one week, at least two weeks, at least three weeks or at least twelve weeks after the completion of one round of the anticancer therapy.
The method of any one of the preceding claims, wherein the suppressing agent is administered prior to the completion of one round of the anticancer therapy.
The method of any one of the preceding claims, wherein the suppressing agent is administered at least one week, at least two weeks, at least three weeks or at least twelve weeks after the initiation of the anticancer therapy.
The method of any one of the preceding claims, wherein the subject is being treated for melanoma, non-small cell lung cancer (NSCLC), Hodgkin's lymphoma, head and neck cancer, renal cell cancer, bladder cancer, or Merkel cell carcinoma.
The method of any one of the preceding claims, further comprising administering a steroid as a second suppressing agent.
The method of any one of the preceding claims, wherein the suppressing agent comprises infliximab.
The method of any of the preceding claims, further comprising administering infliximab as a second suppressing agent.
A composition comprising the anticancer agent of any one of the preceding claims and the suppressing agent of any one of the preceding claims.
A kit comprising an agent for detecting a biomarker for an adverse event and the suppressing agent of any one of the preceding claims.
A kit comprising the anticancer agent of any one of the preceding claims, an agent for detecting a biomarker for an adverse event and the suppressing agent of any one of the preceding claims.
Dependencies are inferred from the claim text.